SCHEMBL1455121

SCHEMBL1455121

Nc1cc(NC(=O)c2ccc(Cl)cc2)ccc1Sc1ccc(O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.57
KDM4E B2RXH2 3/20 0.57
ALDH1A1 P00352 3/20 0.57
HPGD P15428 3/20 0.57
LMNA P02545 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
NPSR1 Q6W5P4 1/20 0.57
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
RECQL P46063 1/20 0.46
NQO2 P16083 1/20 0.44
PRMT1 Q99873 1/20 0.44
KCNQ3 O43525 2/20 0.44
KCNQ2 O43526 2/20 0.44
SNCA P37840 1/20 0.44
ALOX15 P16050 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1455344 0.94 NQO2 (0.50) MAPTKDM4EALDH1A1HPGDLMNA
SCHEMBL1455186 0.88 MEN1 (0.57) MAPTKDM4EALDH1A1HPGDLMNA
SCHEMBL1455484 0.88 ALDH1A1 (0.57) MAPTKDM4EALDH1A1HPGDLMNA
SCHEMBL1454120 0.88 TP53 (0.51) MAPTKDM4EALDH1A1HPGDLMNA
SCHEMBL1454847 0.88 DEGS1 (0.49) MAPTKDM4ENPC1RAB9AKMT2A
SCHEMBL1454271 0.87 KCNK3 (0.51) MAPTHPGDNPC1RAB9AKMT2A
SCHEMBL1454472 0.87 CACNA1B (0.48) MAPTKDM4EALDH1A1HPGDLMNA
SCHEMBL1455071 0.86 PTGS1 (0.53) MAPTKDM4EALDH1A1HPGDLMNA
SCHEMBL1454704 0.85 NPC1 (0.53) MAPTKDM4EALDH1A1HPGDLMNA
SCHEMBL1455527 0.85 KCNK3 (0.49) MAPTKDM4EALDH1A1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979348-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-01-18 EP disclosed
US-7910595-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-22 US disclosed
CN-101384591-A Antiviral compounds ABBOTT LAB (US) 2009-03-11 CN disclosed
EP-1979348-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232627-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076034-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232627-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 MAPT 1347/4885KDM4E 1822/4885ALDH1A1 2723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.